Scarica l'app Stockscreener
75.25
0.27%
-0.20
Pre-mercato:
75.90
0.65
+0.86%
Precedente Chiudi:
$75.45
Aprire:
$75.84
Volume 24 ore:
850.25K
Relative Volume:
0.40
Capitalizzazione di mercato:
$12.44B
Reddito:
$1.06B
Utile/perdita netta:
$-326.58M
Rapporto P/E:
-35.80
EPS:
-2.1022
Flusso di cassa netto:
$-977.73M
1 W Prestazione:
+4.83%
1M Prestazione:
+0.62%
6M Prestazione:
+0.76%
1 anno Prestazione:
+123.66%
Intervallo 1D:
$74.82
$76.96
Intervallo di 1 settimana:
$71.30
$77.76
Portata 52W:
$31.66
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
75.25 | 12.44B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
MSN Money - MSN
Form 144: Option exercises listed; Joseph Loscalzo sold shares (IONS) - Stock Titan
Ionis well-positioned for continued momentum and substantial valu - The National Law Review
Ionis to host 2026 virtual Annual Meeting of Stockholders - BioSpace
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market - openPR.com
Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com
Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks - TipRanks
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Discipline and Rules-Based Execution in IONS Response - Stock Traders Daily
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
VY(R) T. Rowe Price Diversified Mid Cap Growth Portfolio's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Teladoc (TDOC) - The Globe and Mail
Ionis Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Ionis to present at upcoming investor conferences - The National Law Review
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold - Moomoo
Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Ionis Pharmaceuticals (IONS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
IONS Maintained by Barclays -- Price Target Raised to $115 - GuruFocus
Atle Fund Management AB's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus
Ionis Pharmaceuticals Projects Ozarsen Sales Exceeding 3 Billion Dollars - HarianBasis.co
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com
Narrow-Moat Ionis' Peak Sales Raised for Olezarsen; Positive Outlook as Late-Stage Assets Advance - Morningstar
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
IONS Maintained by RBC Capital -- Price Target Raised to $100 - GuruFocus
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating - marketscreener.com
Vanguard reports 5.05% stake in Ionis Pharmaceuticals (NASDAQ: IONS) - Stock Titan
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View - TradingView
Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $86 - Moomoo
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $100 to $125 - Moomoo
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals Q1 2026 earnings preview - MSN
IONS Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - GuruFocus
Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity By Investing.com - Investing.com India
IONS SWOT Analysis: Strong Revenue Growth Amidst Challenges Reve - GuruFocus
Ionis Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IONS) 2026-04-29 - Seeking Alpha
Oppenheimer raises Ionis Pharmaceuticals price target on guidance By Investing.com - Investing.com Canada
Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity - Investing.com
Ionis outlines 2026 revenue of $875M-$900M while lifting olezarsen peak sales view to >$3B - MSN
Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Ionis Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c) - TipRanks
Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Quarterly Earnings Results - MarketBeat
Ionis gains on late-stage trial win for hypertriglyceridemia therapy - MSN
Ionis Pharmaceuticals Q1: Revenue $246.1M, EPS (loss) $0.56 — 10-Q Summary - TradingView
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):